Clinical Trial Update: Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a combination of QLS31905, QL2107, and chemotherapy as first-line therapy for CLDN18.2-positive unresectable locally advanced or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• QL2107
• QLS31905

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING